HC Wainwright Has Bullish Estimate for TRAX Q2 Earnings

First Tracks Biotherapeutics (NASDAQ:TRAX) – Analysts at HC Wainwright lifted their Q2 2026 earnings per share (EPS) estimates for First Tracks Biotherapeutics in a research note issued to investors on Friday, July 10th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.86) per share for the quarter, up from their prior forecast of ($0.90). HC Wainwright has a “Buy” rating and a $44.00 price objective on the stock. HC Wainwright also issued estimates for First Tracks Biotherapeutics’ FY2029 earnings at ($2.66) EPS and FY2030 earnings at ($1.44) EPS.

A number of other research analysts have also recently commented on TRAX. UBS Group assumed coverage on First Tracks Biotherapeutics in a report on Tuesday, April 21st. They issued a “buy” rating and a $45.00 price target on the stock. Wedbush began coverage on shares of First Tracks Biotherapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $30.00 price objective on the stock. Leerink Partners began coverage on shares of First Tracks Biotherapeutics in a report on Friday, April 24th. They issued an “outperform” rating and a $46.00 target price on the stock. Barclays began coverage on shares of First Tracks Biotherapeutics in a research report on Wednesday, April 22nd. They set an “overweight” rating and a $40.00 target price for the company. Finally, Piper Sandler initiated coverage on First Tracks Biotherapeutics in a research report on Monday, May 4th. They set an “overweight” rating and a $54.00 price objective for the company. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, First Tracks Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

First Tracks Biotherapeutics Trading Down 3.4%

NASDAQ:TRAX opened at $35.01 on Tuesday. The firm’s 50-day simple moving average is $18.69. First Tracks Biotherapeutics has a 52 week low of $14.72 and a 52 week high of $38.49. The company has a market capitalization of $1.22 billion and a PE ratio of -19.03.